Gerresheimer (GXI) Stock Overview
Provides drug containment solutions in Germany and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
GXI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Gerresheimer AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €26.76 |
| 52 Week High | €24.48 |
| 52 Week Low | €18.19 |
| Beta | 0.48 |
| 1 Month Change | 5.85% |
| 3 Month Change | 14.26% |
| 1 Year Change | -64.60% |
| 3 Year Change | -64.60% |
| 5 Year Change | -64.60% |
| Change since IPO | -50.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| GXI | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 3.6% | -3.7% | -2.8% |
| 1Y | -64.6% | 0.9% | 11.4% |
Return vs Industry: GXI underperformed the Swiss Life Sciences industry which returned 1.1% over the past year.
Return vs Market: GXI underperformed the Swiss Market which returned 11% over the past year.
Price Volatility
| GXI volatility | |
|---|---|
| GXI Average Weekly Movement | 3.5% |
| Life Sciences Industry Average Movement | 5.3% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 2.0% |
Stable Share Price: GXI has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: GXI's weekly volatility has decreased from 11% to 4% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1864 | 13,528 | Uwe Röehrhoff | www.gerresheimer.com |
Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization, and contract manufacturing of drug delivery programs; project and quality management; and drug delivery devices, including inhalers, injection/auto injectors, and pen injectors.
Gerresheimer AG Fundamentals Summary
| GXI fundamental statistics | |
|---|---|
| Market cap | CHF 922.99m |
| Earnings (TTM) | -CHF 303.32m |
| Revenue (TTM) | CHF 2.20b |
Is GXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GXI income statement (TTM) | |
|---|---|
| Revenue | €2.32b |
| Cost of Revenue | €1.77b |
| Gross Profit | €548.29m |
| Other Expenses | €868.61m |
| Earnings | -€320.32m |
Last Reported Earnings
Nov 30, 2025
Next Earnings Date
Oct 15, 2026
| Earnings per share (EPS) | -9.27 |
| Gross Margin | 23.62% |
| Net Profit Margin | -13.80% |
| Debt/Equity Ratio | 198.6% |
How did GXI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 12:27 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2025/11/30 |
| Annual Earnings | 2025/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gerresheimer AG is covered by 30 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Jain | Barclays |
| Jonathon Unwin | Barclays |
| Pallav Mittal | Barclays |